Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-6 months of chemotherapy. Usual care …
Sponsor: NRG Oncology
NCT ID: NCT06958328
Sites in New York: - New York-Presbyterian/Brooklyn Methodist Hospital — Brooklyn, New York
- Memorial Sloan Kettering Commack — Commack, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
- NYU Langone Hospital - Long Island — Mineola, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone — New York, New York
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
Sponsor: Incyte Corporation
NCT ID: NCT07522073
Sites in New York: - Investigative Site US059 — Lake Success, New York
- Investigative Site US031 — New York, New York
- Investigative Site US041 — New York, New York
- Investigative Site US004 — New York, New York
- Investigative Site US003 — New York, New York
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to assess the safety and efficacy of BMS-986504, a selective, MTA-cooperative PRMT5 inhibitor, in combination with Nab-paclitaxel/Gemcitabine (nab-p/gem) versus placebo in combination with nab-p/gem, in partici…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07076121
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Northwell Health/ RJ Zuckerberg Cancer Center — Lake Success, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone — Mineola, New York
- NYU Winthrop Hospital — Mineola, New York
- Local Institution - 0140 — New York, New York
Phase 3 Recruiting Industry
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting o…
Sponsor: Pierre Fabre Medicament
NCT ID: NCT03394365
Sites in New York: - Weill Cornell Medicine (Adults only) — New York, New York
- Columbia University Medical Center (Adults and Pediatrics) — New York, New York
- Memorial Sloan Kettering Cancer Center (Adults and Pediatrics) — New York, New York
- Montefiore Medical Center (Adults only) — The Bronx, New York
- Montefiore Medical Center (Pediatrics only) — The Bronx, New York
Phase 2, Phase 3 Recruiting Industry
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
Sponsor: Exelixis
NCT ID: NCT06943755
Sites in New York: - Exelixis Clinical Site #59 — Buffalo, New York
- Exelixis Clinical Site #7 — New York, New York
- Exelixis Clinical Site #53 — Rochester, New York
Phase 2, Phase 3 Recruiting Industry
The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcino…
Sponsor: Panbela Therapeutics, Inc.
NCT ID: NCT05254171
Sites in New York: - Columbia University Medical Center — New York, New York
- University of Rochester — Rochester, New York
Phase 3 Recruiting Industry
Pancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic). The standard treatment is chemotherapy, but other treatments are needed to imp…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07409272
Sites in New York: - NYU Long Island Mineola — Mineola, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone — New York, New York
- White Plains Hospital Center for Cancer Care - Oncology — White Plains, New York
Phase 3 Recruiting Academic/Other
Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
Sponsor: Johns Hopkins University
NCT ID: NCT02000089
Sites in New York: - NYU Langone Medical Center — New York, New York
- Columbia University Medical Center — New York, New York
Phase 3 Recruiting Academic/Other
The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).
Sponsor: Rezolute
NCT ID: NCT06881992
Sites in New York: - Investigative Site — New York, New York
Phase 2 Recruiting NIH
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04858334
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Memorial Sloan Kettering Commack — Commack, New York
- Northwell Health Cancer Institute at Huntington — Greenlawn, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
- Northwell Health/Center for Advanced Medicine — Lake Success, New York
Phase 2 Recruiting Network
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05040360
Sites in New York: - Upstate Cancer Center at Oswego — Oswego, New York
- Stony Brook University Medical Center — Stony Brook, New York
- State University of New York Upstate Medical University — Syracuse, New York
- SUNY Upstate Medical Center-Community Campus — Syracuse, New York
- Montefiore Medical Center-Einstein Campus — The Bronx, New York
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in partici…
Sponsor: Genentech, Inc.
NCT ID: NCT05968326
Sites in New York: - Memorial Sloan Kettering Cancer Center - Commack — Commack, New York
- Memorial Sloan Kettering Cancer Center at Westchester — Harrison, New York
- Northwell Health — Lake Success, New York
- NYU Langone Health — New York, New York
- Mount SInai Medical Center — New York, New York
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in New York: - NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center — New York, New York
Phase 1, Phase 2 Recruiting Industry
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in New York: - Columbia University — New York, New York
- NYU Langone Health — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in New York: - NYU Langone Health — New York, New York
- Icahn School of Medicine At Mount Sinai Prime — New York, New York
- Clinical Research Alliance — Westbury, New York
Phase 1, Phase 2 Recruiting Industry
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT05379985
Sites in New York: - Perlmutter Cancer Center at NYU Langone Health — New York, New York
- Memorial Sloan-Kettering Cancer Center — New York, New York
- Columbia University — New York, New York
Phase 1, Phase 2 Recruiting Industry
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specif…
Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT05732831
Sites in New York: - New York University Langone Health — New York, New York
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to avai…
Sponsor: VM Oncology, LLC
NCT ID: NCT03556228
Sites in New York: - Weill Cornell Medicine, Cornell University (site 126) — New York, New York
Phase 1, Phase 2 Recruiting Industry
This is a study to evaluate the safety and potential anti-tumor activity of an investigational agent called ARV-806 in Adults with Advanced Cancer having a specific KRAS mutation. This is an open-label study which means that participants a…
Sponsor: Arvinas Inc.
NCT ID: NCT07023731
Sites in New York: - Clinical Trial Site — New York, New York
- Clinical Trial Site — New York, New York
Phase 1, Phase 2 Recruiting Industry
Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the bo…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06428409
Sites in New York: - Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0327) — Mineola, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0324) — New York, New York
Phase 1, Phase 2 Recruiting Industry
This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.
Sponsor: Verastem, Inc.
NCT ID: NCT07020221
Sites in New York: - Laura & Isaac Perlmutter Cancer Center at NYU Langone — New York, New York
Phase 1, Phase 2 Recruiting Industry
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab…
Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT06922591
Sites in New York: - NYU Langone Health — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
Phase 1, Phase 2 Recruiting Industry
The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesoth…
Sponsor: A2 Biotherapeutics Inc.
NCT ID: NCT06051695
Sites in New York: - NYU Langone Medical Center — New York, New York
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab or docetaxel in participants with advanced solid tumors. This study is a first-in-human…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT04895709
Sites in New York: - Local Institution - 0006 — New York, New York
- Local Institution - 0002 — New York, New York
Phase 1, Phase 2 Recruiting Industry
This Phase 1/2, first-in-human, open-label, multicenter study follows a 3+3 ascending dose escalation design to determine the MTD/RP2D and to characterize the safety, tolerability, PK, and antitumor effects of LNS8801 alone and in combinat…
Sponsor: Linnaeus Therapeutics, Inc.
NCT ID: NCT04130516
Sites in New York: - Columbia University Herbert Irving Comprehensive Cancer Center — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York